Myeloma and amyloid Mini-review: highlights of cardio-oncology
Article Sidebar
Published:
Feb 3, 2016
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Blaes A, Sawyer D, Lenihan D. Myeloma and amyloid. OncoReview [Internet]. 2016Feb.3 [cited 2024Nov.23];6(1(21):5-. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/468
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Kumar SK, Dispenzieri A, Lacy MQ et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122-1128.
2. Attal M, Lauwers-Cances V, Hulin C et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 Trial). Blood 2015; 126(23).
3. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352(24): 2487-2498.
4. San Miguel JF, Schlag R, Khuageva NK et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359(9): 906-917.
5. Stewart AK, Rajkumar SV, Dimopoulos MA et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372(2): 142-152.
6. Shah JJ, Stadtmauer EA, Abonour R et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015; 126(20): 2284-2290.
7. Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res 2015; 21(21): 4767-4773.
8. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction – Alzheimer’s disease of the heart? N Engl J Med 2013; 368(5): 455-464.
9. Herrmann J, Wohlert C, Saguner AM et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 2013; 15(6): 614-623.
10. Ranek MJ, Zheng H, Huang W et al. Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload. J Mol Cell Cardiol 2015; 85: 273-281.
11. Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS One 2014; 9(1): e87671.
12. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98(11): 1753-1761.
13. Atrash S, Tullos A, Panozzo S et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 2015; 5: e272.
14. Danhof S, Schreder M, Rasche L et al. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. Eur J Haematol 2015. http://doi.org/10.1111/ejh.12677.
15. Sayago I. Impact of proteosomal inhibitors on cardiac AL amyloid. Heart Failure Association 2015 Summer Congress.
16. D’Souza A, Dispenzieri A, Wirk B et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J Clin Oncol 2015; 33(32): 3741-3749.
17. Cornell RF, Zhong X, Arce-Lara C et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant 2015; 50(7): 914-917.
18. Wechalekar AD, Schonland SO, Kastritis E et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121(17): 3420-3427.
19. Wall JS, Kennel SJ, Williams A et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012; 7(12): e52686.
2. Attal M, Lauwers-Cances V, Hulin C et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 Trial). Blood 2015; 126(23).
3. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352(24): 2487-2498.
4. San Miguel JF, Schlag R, Khuageva NK et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359(9): 906-917.
5. Stewart AK, Rajkumar SV, Dimopoulos MA et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372(2): 142-152.
6. Shah JJ, Stadtmauer EA, Abonour R et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015; 126(20): 2284-2290.
7. Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res 2015; 21(21): 4767-4773.
8. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction – Alzheimer’s disease of the heart? N Engl J Med 2013; 368(5): 455-464.
9. Herrmann J, Wohlert C, Saguner AM et al. Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail 2013; 15(6): 614-623.
10. Ranek MJ, Zheng H, Huang W et al. Genetically induced moderate inhibition of 20S proteasomes in cardiomyocytes facilitates heart failure in mice during systolic overload. J Mol Cell Cardiol 2015; 85: 273-281.
11. Xiao Y, Yin J, Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS One 2014; 9(1): e87671.
12. Siegel D, Martin T, Nooka A et al. Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98(11): 1753-1761.
13. Atrash S, Tullos A, Panozzo S et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 2015; 5: e272.
14. Danhof S, Schreder M, Rasche L et al. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. Eur J Haematol 2015. http://doi.org/10.1111/ejh.12677.
15. Sayago I. Impact of proteosomal inhibitors on cardiac AL amyloid. Heart Failure Association 2015 Summer Congress.
16. D’Souza A, Dispenzieri A, Wirk B et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study. J Clin Oncol 2015; 33(32): 3741-3749.
17. Cornell RF, Zhong X, Arce-Lara C et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant 2015; 50(7): 914-917.
18. Wechalekar AD, Schonland SO, Kastritis E et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121(17): 3420-3427.
19. Wall JS, Kennel SJ, Williams A et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012; 7(12): e52686.